ClinTec Sees Rise in Revenues and Growth in the Middle East

ClinTec, a full service multinational contract research organisation (CRO), has today announced that it has achieved organic growth with a 45 per cent increase in global sales revenues over the last twelve months; expanded its client base and signing new contracts with 11 of the world’s top 25 pharmaceutical firms.

With a presence in some 40 countries around the world, ClinTec International manages clinical trials in all major therapeutic areas, including oncology, neurology, cardiovascular, respiratory as well as gastroenterology.

Dr. Rabinder Buttar, the company’s founder, President and CEO commented: “The launch of our Cairo office in October was one of the high points of the year. Apart from providing our global pharmaceutical associates with access to new patient populations, ClinTec Cairo cements our reputation as the major CRO in the Middle East and North Africa (MENA) region."

ClinTec has played a key role in 2009 in facilitating complex restructuring programmes for Global Pharma, who are searching for innovative ways to optimise their R&D efforts. The shift of research delivery from West to East is an area in which ClinTec is able to offer a credible solution for using a blend between flexible resource solutions and off-shore project delivery.